Performance and Target Analysis on NetApp, Inc. (NASDAQ:NTAP), Medtronic, Inc. (NYSE:MDT)

NetApp, Inc. (NASDAQ:NTAP) shares have a current ABR (average broker recommendation) of 2.74. This recommendation is offered by Zacks Research. The rating lands on a sliding numerical scale from 1 to 5. A recommendation of 5 would indicate a Strong Sell, and a 1 would signify a Strong Buy. The mean rating may help provide a general sense of analyst sentiment on company shares.

Sell-side analysts taken into consideration by Zacks have also provided price target estimates on shares of NetApp, Inc. (NASDAQ:NTAP). The highest current target is $62. The lowest price target out of the polled analysts is presently $25. The consensus target price is currently noted at $43.923. Analysts may employ various techniques to help predict future stock price levels.

On the earnings front, NetApp, Inc. (NASDAQ:NTAP) is expected to post quarterly earnings per share of $0.68. This is the current consensus figure provided by Zacks. Investors and analysts will be looking for the company to next post earnings on or around 2017-05-24. NetApp, Inc. (NASDAQ:NTAP) most recently reported quarterly EPS of $0.72 for the quarter ending 2017-01-31. The gap between the actual and the projected estimate leading up to earnings created a surprise factor of 22.03%.

For the current quarter, analysts are expecting Medtronic, Inc. (NYSE:MDT) to report EPS of $1.31. This consensus estimate is provided by Zacks Research. After the period that ended on 2017-01-31, Medtronic, Inc. (NYSE:MDT) reported an EPS actual of $1.12. The difference between the actual and estimate resulted in a surprise factor of 0.9%. The company is expected to release their next earnings report on or around 2017-05-30. Interested parties will be watching to see how company results compare to what the Street was projecting for the fiscal period.

Shares of Medtronic, Inc. (NYSE:MDT) have a current ABR or average broker rating of 1.95. This consensus recommendation is also provided by Zacks Research. The recommendation falls on a scale between 1 and 5. A broker rating of 1 would translate into a Strong Buy. A rating of 5 would indicate a Strong Sell recommendation. This consensus broker rating may help shed some light on how the sell-side is currently viewing company stock.

Covering analysts often provide target price projections for company shares. The current Zacks consensus target price on shares of Medtronic, Inc. (NYSE:MDT) is $87.562. The top analyst target is $96, and the lowest target is $80 on the stock. Because of the different techniques used to gauge a company target price, estimates may be quite different from one analyst to another.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Comment